NovImmune
is committed to innovation by discovering and developing therapeutic monoclonal antibodies to treat patients suffering from immune-related
disorders.
NovImmune is actively seeking to explore opportunities for in- and out-licensing collaborations with pharmaceutical, biotechnology, and academic partners.
NovImmune is expanding its commercially attractive and balanced pipeline of therapeutic mAbs at various stages of clinical and preclinical development.
